Release details

2016-03-11 13:05 CET
  • Print
  • Share Share
en

Bionor Pharma ASA completes extraordinary general meeting

BIONOR PHARMA ASA

STOCK EXCHANGE ANNOUNCEMENT

Bionor Pharma ASA completes extraordinary general meeting

(Oslo, Norway, 11 March 2016) Bionor Pharma ASA (OSE:BIONOR) has today completed an Extraordinary General Meeting (EGM), which elected a new Board of Directors according to the unanimous proposal from the Nomination Committee announced 8 March 2016. Following the Extraordinary General Meeting, the Board is composed as follows:

· Per Thoresen as newly elected Chairman of the Board
· Lars H. Høie as new Board Member
· Jerome B. Zeldis as re-elected Board Member
· Benedicte Fossum as re-elected Board Member
· Thomas Hofstaetter as re-elected Board Member
· Kirsten Drejer as re-elected Board Member
· Ingrid Leisner as new Board Member

Please see the attached minutes from the meeting in Norwegian and English translation.

This information is published in accordance with the requirements of the Continuing Obligations.

Further information
David Horn Solomon, President and CEO, +45 22 20 63 00, dhs@bionorpharma.com
Jens Krøis, CFO, +45 20 80 16 68, jk@bionorpharma.com
Jørgen Fischer Ravn, VP Investor Relations & Communications, +45 20 30 39 03, jfr@bionorpharma.com

About Bionor
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a functional HIV cure. The company believes it has first mover potential based on clinical results to date and early adoption of now recognized clinical strategy. In December 2015, Bionor announced that the HIV 'Shock & Kill' trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by significantly reducing latent HIV reservoir and further demonstrated control of viral load. Bionor is currently planning BIOSKILL, a proof-of-concept Phase II trial, which may lead to a major value inflection point and partnering opportunities. Bionor currently retains full ownership rights to Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company. Bionor is based in Oslo, Norway, and also has offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com.

HUG#1993718